Citadel Advisors’s Kindred Biosciences, Inc. KIN Stock Holding History

Citadel Advisors’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-49,600	Closed	-$455K	–	15278
2021 Q2	$455K	Buy	49,600 +24,400	+97%	+$142K	﹤0.01%	10264
2021 Q1	$125K	Sell	25,200 -2,100	-8%	-$10.1K	﹤0.01%	12256
2020 Q4	$118K	Sell	27,300 -1,000	-4%	-$4.07K	﹤0.01%	10118
2020 Q3	$121K	Buy	28,300 +12,700	+81%	+$53.1K	﹤0.01%	9157
2020 Q2	$70K	Buy	+15,600	New	+$69.7K	﹤0.01%	9166

Other funds holding KIN

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Citadel Advisors's KIN Position: Q3 2021 in Review

Citadel Advisors sold out of Kindred Biosciences, Inc. (KIN) in Q3 2021, closing a stake of 16,369 shares — an estimated $150K sold.

Citadel Advisors first reported a position in KIN in Q1 2014 and held it in 11 quarters. The position peaked at $373K in Q3 2018. 1 fund tracked by Wall St. Rank holds KIN as of Q3 2021.

Citadel Advisors reported no remaining Kindred Biosciences, Inc. position as of Q3 2021 after selling out during the quarter.
Citadel Advisors sold 16,369 Kindred Biosciences, Inc. shares in Q3 2021, an estimated $150K.
Citadel Advisors first reported a position in Kindred Biosciences, Inc. in Q1 2014 and held it in 11 quarters.
Citadel Advisors's Kindred Biosciences, Inc. position peaked at $373K in Q3 2018.
1 fund tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2021.

Based on Citadel Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.